Skip to Content
Download Image
Enterprise

UAB teams with biotech firm Altimmune to test potential COVID-19 vaccine

BIRMINGHAM, Alabama — The University of Alabama at Birmingham announced today that it is launching a collaboration with biopharmaceutical company Altimmune for preclinical testing of a potential vaccine to prevent COVID-19 disease.

The testing at UAB will investigate immune responses to the vaccine in mice — a key step before Altimmune can launch a Phase 1 human trial in patients in the fall of this year.

The COVID-19 vaccine, called AdCOVID, is a single-dose vaccine candidate delivered by a nasal spray.

Gaithersburg, Maryland-based Altimmune has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.

Download Image
Innovation

UAB to participate in global clinical trial for coronavirus treatment

Stay connected to what's happening in Alabama now.

  • Enter your email address to receive periodic updates on the evolution of business in Alabama.

Ready to start your company's next chapter in Alabama?

Alabama may be small in size, but its ability to accommodate businesses seeking success is vast. See why companies like Mercedes, Airbus, Hyundai, and Honda have decided to call Alabama home.

Find A Site Learn More About Alabama